PARP1 and fatty liver disease: The inhibition of PARP-1 can increase NAD+ content and SIRT1 activity, enhance lipid metabolism, and improve hepatic steatosis in hepatocytes under oxidative stress and mice fed a high-fat diet (Kraus and Hottiger, 2013).